Anzeige
Mehr »
Donnerstag, 24.07.2025 - Börsentäglich über 12.000 News
Lizenz aktiviert - Kooperation fix: Diese Aktie will jetzt den Milliardenmarkt erobern!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A40GMU | ISIN: US71880W5013 | Ticker-Symbol: 44R1
NASDAQ
24.07.25 | 21:52
2,510 US-Dollar
-0,79 % -0,020
Branche
Biotechnologie
Aktienmarkt
Sonstige
1-Jahres-Chart
PHIO PHARMACEUTICALS CORP Chart 1 Jahr
5-Tage-Chart
PHIO PHARMACEUTICALS CORP 5-Tage-Chart

Aktuelle News zur PHIO PHARMACEUTICALS Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
07.07.Phio Pharmaceuticals Corp. - 8-K, Current Report6
26.06.Phio Pharma stock maintains buy rating as cancer trial advances9
PHIO PHARMACEUTICALS Aktie jetzt für 0€ handeln
26.06.Phio Pharmaceuticals Corp. - 8-K, Current Report-
25.06.Phio's PH-762 shows positive safety profile in fourth cohort trial5
25.06.Phio Pharmaceuticals Corp.: Phio Pharmaceuticals Announces Positive Safety Monitoring Committee Recommendation to Advance INTASYL PH-762 Skin Cancer Clinical Trial to Fifth Dose Escalation Cohort258-Phio's lead clinical siRNA compound PH-762 demonstrates supportive safety profile in fourth cohort, permitting dose escalation in expected final cohortMarlborough, Massachusetts--(Newsfile Corp. -...
► Artikel lesen
24.06.Phio Pharmaceuticals Corp.: Phio Pharmaceuticals Announces Participation in the Renmark Financial Communications Virtual Non-Deal Roadshow Series196Marlborough, Massachusetts--(Newsfile Corp. - June 24, 2025) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO) is a clinical-stage siRNA biopharmaceutical company developing therapeutics using its proprietary...
► Artikel lesen
12.06.Phio Pharmaceuticals Corp. - 8-K, Current Report3
06.06.Phio Pharmaceuticals ernennt neue Vizepräsidenten für Strategie und Finanzen10
06.06.Phio Pharmaceuticals appoints new strategic and finance VPs1
06.06.Phio Pharmaceuticals Corp.: Phio Pharmaceuticals Announces Strategic Initiative to Create Awareness of the Comprehensive INTASYL siRNA Portfolio375- Robert Infarinato named VP, Strategic Development- Lisa Carson named as new VP, Finance and AdministrationMarlborough, Massachusetts--(Newsfile Corp. - June 6, 2025) - Phio Pharmaceuticals Corp....
► Artikel lesen
05.06.H.C. Wainwright nimmt Phio Pharma-Aktie mit Kaufempfehlung in Coverage auf14
05.06.H.C. Wainwright assumes coverage on Phio Pharma stock with Buy rating4
19.05.Phio Pharmaceuticals Corp.: Phio Pharmaceuticals Announces Participation in the Sidoti Micro-Cap Virtual Investor Conference467Marlborough, Massachusetts--(Newsfile Corp. - May 19, 2025) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO) is a clinical-stage siRNA biopharmaceutical company developing therapeutics using its proprietary...
► Artikel lesen
15.05.Phio Pharmaceuticals Corp. - 8-K, Current Report5
15.05.Phio Pharmaceuticals Corp.: Phio Pharmaceuticals Reports First Quarter 2025 Financial Results and Provides Business Update446Clinical trial advances for INSTASYL siRNA lead product candidate PH-762 4th Cohort enrolling and treating patients in on-going clinical studyMarlborough, Massachusetts--(Newsfile Corp. - May 15, 2025)...
► Artikel lesen
07.05.Phio berichtet über positive Ergebnisse in Hautkrebs-Studie13
07.05.Phio reports positive results in skin cancer trial2
07.05.Phio Pharmaceuticals Corp.: Phio Pharmaceuticals Announces Positive Pathology Results in Third Cohort in INTASYL PH-762 Skin Cancer Clinical Trial318Complete Pathologic Response reported in 2 patients in the Third Cohort with cutaneous squamous cell carcinoma, complementing results in prior cohort Phio to present trial results to date at a podium...
► Artikel lesen
01.05.Phio Pharmaceuticals Corp.: Phio Pharmaceuticals Announces Participation in the Renmark Financial Communications Virtual Non-Deal Roadshow Series266Marlborough, Massachusetts--(Newsfile Corp. - May 1, 2025) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO) is a clinical-stage siRNA biopharmaceutical company developing therapeutics using its proprietary...
► Artikel lesen
22.04.Phio Pharmaceuticals Corp. - 8-K, Current Report18
Weiter >>
68 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1